Rifampicin is an antibiotic that potently inhibits RNA polymerase and blocks RNA synthesis in Escherichia coli. Rifampicin has been shown to inhibit α-synuclein fibrillation and disaggregate fibrils in a concentration-dependent manner. Data indicates that Rifampicin can activate the nuclear pregnane X receptor, which affects cytochrome P450, and the activity of glucuronosyltransferases and P-glycoprotein. Rifampicin has been shown to enhance CYP2C-mediated metabolism, affect compounds that are transported by P-glycoprotein and metabolized by CYP3A4. Rifampicin has been used in tuberculosis studies.
1. Sundaram, K.S. and Lev, M. 1984. J. Neurochem. 42: 577-581. PMID: 6693888
2. Shukla, G.S., et al. 1991. Biochim. Biophys. Acta. 1083: 101-108. PMID: 1827738
3. Mizrachi, Y., et al. 1996. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 11: 137-141. PMID: 8556395
4. Cho, J.Y. 2007. Biol. Pharm. Bull. 30: 2105-2112. PMID: 17978484
See how others have used Rifampicin (CAS 13292-46-1). Click on the entry to view the PubMed entry .
PMID: # 28696235 Heine, HS. et al. 2017. Antimicrob. Agents Chemother. 61:
PMID: # 25019701 Zou, Z. et al. 2014. Journal of drug targeting. 22: 839-48.
PMID: # 17595319 Echchgadda, I. et al. 2007. Mol. Endocrinol. 21: 2099-2111.
PMID: # 409709 Grüneberg, RN. et al. 1977. J. Antimicrob. Chemother. 3: 453-457.